In these updated definitions, mutations of the cohesin subunit SA-2 (STAG2) are recognized as a defining alteration of AML with myelodysplasia-related gene mutations (in absence of other defining alterations) irrespective of prior presence of myelodysplastic neoplasms [3]. This evidence concerns the gene STAG2 and acute myeloid leukemia.